European Journal of Pharmacology: Molecular Pharmacology
Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor
References (14)
- et al.
Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands
Mol. Pharmacol.
(1990) - et al.
Identification of angiotensin II receptor subtypes
Biochem. Biophys. Res. Commun.
(1989) - et al.
[3H]DUP753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtype
Biochem. Biophys. Res. Commun.
(1990) - et al.
Possible implication of peptidase activity in different potency of angiotensins II and III for displacing [125I]angiotensin II binding in pig aorta
Eur. J. Pharmacol.
(1992) - et al.
The pharmacological characterization of FK739, a new angiotensin II-receptor antagonist
Jan. J. Pharmacol.
(1993) - et al.
Nonpeptide angiotensin II receptor antagonists
Trends Pharmacol. Sci.
(1991) - et al.
Preliminary biochemical characterization of two angiotensin II receptor subtypes
Biochem. Biophys. Res. Commun.
(1989)
Cited by (26)
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets
2017, Bioorganic and Medicinal Chemistry LettersAngiotensin II type 1 receptor antagonists: Why do some of them produce insurmountable inhibition?
2000, Biochemical PharmacologyCitation Excerpt :Such a method has also been described by Hara et al.[19] and relies on a competitive interaction between these ligands. Moreover, this method is not ‘biased’ by eventual reassociation of the unlabelled antagonists, as this is prevented by the radioligand itself [19]. The corresponding rate constants, therefore, reflect the ‘true’ dissociation of the antagonist from the receptor and should be compared with the functional recovery experiment by washout of the cells in the presence of losartan.
Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors
2000, Biochemical PharmacologyCitation Excerpt :On the other hand, nearly no appreciable acceleration of the recovery was observed for irbesartan. In the second approach, we have compared the slowing of the association rate of [3H]candesartan after pretreatment of CHO-AT1 cells with unlabelled antagonists, a method similar to that described by Hara et al. [15] and one which relies on a competitive interaction between these ligands. In these experiments, [3H]candesartan not only serves as the radioligand but also prevents the (re)occupation of the receptor by the unlabelled antagonists.
The assessment of antagonist potency under conditions of transient response kinetics
1999, European Journal of PharmacologyInsurmountable angiotensin AT<inf>1</inf> receptor antagonists: The role of tight antagonist binding
1999, European Journal of PharmacologyPharmacological profiles of a novel non-peptide angiotensin II type I receptor antagonist HR720 in vitro and in vivo
1997, Japanese Journal of Pharmacology